Valuation: Celcuity Inc.

Market Cap 4.05B 3.51B 3.31B 3B 5.63B 388B 5.67B 39.55B 15.22B 197B 15.2B 14.86B 628B P/E 2026 *
-16.8x
P/E 2027 * -56.2x
Enterprise Value 4.05B 3.51B 3.31B 3B 5.63B 388B 5.67B 39.55B 15.22B 197B 15.2B 14.86B 628B EV / Sales 2026 *
109x
EV / Sales 2027 * 10.9x
Free-Float
89.77%
Yield 2026 *
-
Yield 2027 * -
1 day-0.99%
1 week-11.09%
Current month-7.14%
1 month-10.11%
3 months-6.28%
6 months-27.60%
Current year-17.08%
1 week 80.62
Extreme 80.62
89.48
1 month 80.62
Extreme 80.62
98
Current year 78.6
Extreme 78.6
151.02
1 year 44.42
Extreme 44.42
151.02
3 years 7.58
Extreme 7.575
151.02
5 years 4.81
Extreme 4.81
151.02
10 years 4.03
Extreme 4.03
151.02
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 01/01/2012
Chief Executive Officer 64 01/01/2012
Director of Finance/CFO 59 01/07/2017
Director TitleAgeSince
Chairman 64 01/01/2012
Director/Board Member 64 01/01/2012
Director/Board Member 67 01/02/2014
Date Insider Type Main position Quantity % Market Cap. Importance
14/8/26 Free

Chief Financial Officer

26,000 0.0562%
14/8/26 Free

Founder

30,000 0.0648%
14/8/26 Free

Chief Executive Officer

200,000 0.4322%
Change 5-day change 1-year change 3-year change Capi.($)
+0.39%-11.09%+50.17%+694.43% 4.05B
-1.38%+0.20%+46.42%+96.33% 69.18B
-0.86%-1.60%+35.01%+74.40% 62B
-0.02%-3.98%-16.22%+350.66% 26.19B
+1.46%+2.25%+28.84%+14.54% 25.75B
+0.33%-2.00%-1.22%-14.48% 24.29B
+3.37%+3.94%+24.99%-14.79% 19.84B
+1.26%-14.23%+170.04%+298.75% 15.65B
+0.98%+0.69%-8.13%+830.48% 13.88B
-0.39%-4.24%-9.86%+454.94% 14.09B
Average -0.96%-3.25%+32.00%+278.53% 27.49B
Weighted average by Cap. -1.01%-1.49%+31.94%+165.92%

Financials

2026 *2027 *
Net sales 37.05M 32.09M 30.35M 27.47M 51.56M 3.55B 51.95M 362M 139M 1.8B 139M 136M 5.75B 370M 321M 303M 274M 515M 35.5B 519M 3.62B 1.39B 18B 1.39B 1.36B 57.41B
Net income -265M -229M -217M -196M -368M -25.39B -371M -2.59B -995M -12.87B -994M -972M -41.05B -72.22M -62.56M -59.16M -53.56M -101M -6.93B -101M -706M -272M -3.51B -271M -265M -11.2B
Net Debt - -
Logo Celcuity Inc.
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
Employees
155
Date Price Change Volume
16/09/26 USD 82.70 -0.99% 783,662
14/09/26 USD 83.53 +0.10% 1,645,972
11/09/26 USD 83.45 -2.39% 863,369
10/09/26 USD 85.49 -5.10% 1,069,434
09/09/26 USD 90.08 -3.16% 708,294
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
82.70USD
Average target price
161.09USD
Spread / Average Target
+94.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CELC Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!